CIGNA announced a positive coverage policy for minimally invasive sacroiliac (SI) joint fusion exclusive for FDA-cleared implants that are placed across the SI joint to promote bone fusion, such as SI-BONE’s iFuse Implant System.
CIGNA, the fourth-largest U.S. commercial health plan, covers nearly 15 million lives.
“As a result of this positive coverage decision, CIGNA’s members will have access to the iFuse procedure when deemed medically necessary by their surgeons,” said Jeffrey Dunn, President, CEO and Chairman of SI-BONE. “CIGNA’s decision to cover MIS SI joint fusion is a significant milestone in the continuing adoption of this important treatment for patients with SI joint dysfunction due to degenerative sacroiliitis or SI joint disruption.”
As noted in the company’s 3Q19 earnings call, SI-BONE is preparing for an expansion of distribution. The company started 2019 with 67 total sales reps and is on track to have between 102 and 112 total reps by year-end.
CIGNA announced a positive coverage policy for minimally invasive sacroiliac (SI) joint fusion exclusive for FDA-cleared implants that are placed across the SI joint to promote bone fusion, such as SI-BONE's iFuse Implant System.
CIGNA, the fourth-largest U.S. commercial health plan, covers nearly 15 million lives.
“As a result of this...
CIGNA announced a positive coverage policy for minimally invasive sacroiliac (SI) joint fusion exclusive for FDA-cleared implants that are placed across the SI joint to promote bone fusion, such as SI-BONE’s iFuse Implant System.
CIGNA, the fourth-largest U.S. commercial health plan, covers nearly 15 million lives.
“As a result of this positive coverage decision, CIGNA’s members will have access to the iFuse procedure when deemed medically necessary by their surgeons,” said Jeffrey Dunn, President, CEO and Chairman of SI-BONE. “CIGNA’s decision to cover MIS SI joint fusion is a significant milestone in the continuing adoption of this important treatment for patients with SI joint dysfunction due to degenerative sacroiliitis or SI joint disruption.”
As noted in the company’s 3Q19 earnings call, SI-BONE is preparing for an expansion of distribution. The company started 2019 with 67 total sales reps and is on track to have between 102 and 112 total reps by year-end.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
